# Edan Instruments

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edan-instruments

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.edan.com
- Total disclosed funding: $15M
- Latest round: Series B (Dec 24, 2009)
- Investors on record: 3

## About

Edan Instruments Inc. is a healthcare technology company that develops and provides medical devices and diagnostic solutions to enhance healthcare delivery across various settings.Founded in 1995, Edan Instruments Inc. is based in Shenzhen, China, and specializes in medical devices and diagnostic solutions. The company has undergone significant growth since its inception and has successfully completed an IPO in April 2011, raising USD 146.00 mn. The current CEOs are Chao Lin and Lingfeng Kong.EDAN Instruments specializes in the development and provision of medical devices and diagnostic solutions, which include point-of-care testing (POCT) devices, in vitro diagnostics (IVD) systems, ultrasound equipment, and patient monitoring devices. Their offerings serve crucial functions such as blood gas analysis, hematology testing, and real-time patient monitoring. Products include portable and cart-based ultrasound devices, multi-parameter patient monitors, and comprehensive ECG solutions, which are marketed in Asia, Europe, and North America, serving healthcare institutions and professionals.EDAN Instruments operates a revenue model that combines direct sales and partnerships within the healthcare sector. Transactions take place through relationships with hospitals and clinics or distributorship agreements. Clients purchase products like blood gas analyzers and ultrasound systems, supported by service and maintenance agreements. The structured pricing plans reflect the complexity of its medical devices and align with industry standards.Edan Instruments plans to leverage its recent IPO funding to support new product development and market expansion. The company is working on launching several innovative medical devices designed to enhance healthcare delivery. Targeted regions for expansion include additional markets in Asia and Europe by 2023. The capital raised will facilitate investments in R&D and market penetration strategies.

## Funding rounds

- Series B, Dec 24, 2009, $4.5M — SB China Venture Capital, WI Harper Group
- Series A, Dec 5, 2008, $10M — WI Harper Group, MPC

## Investors

- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A, Series B
- MPC — Series A
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series B